MX2017016955A - Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. - Google Patents
Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.Info
- Publication number
- MX2017016955A MX2017016955A MX2017016955A MX2017016955A MX2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A
- Authority
- MX
- Mexico
- Prior art keywords
- cisplatin
- treatment
- compositions
- resveratrol
- proliferation
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses pharmaceutical compositions comprising resveratrol and cisplatin, useful for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. Said compositions are capable of reversing the resistance to cisplatin (or its analogs) observed in the treatment of various cancers, so they are ideal for the treatment where such resistance is present. Also, it addresses the problem of resistance or lack of response developed to the action of chemotherapeutic agents, specifically those that occur in breast cancer of various types. Further, due to the low concentrations of the active ingredients of said compositions, the adverse effects observed by the administration of high concentrations of cisplatin during the treatment of various cancers are diminished or eliminated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017016955A MX2017016955A (en) | 2017-12-20 | 2017-12-20 | Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017016955A MX2017016955A (en) | 2017-12-20 | 2017-12-20 | Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016955A true MX2017016955A (en) | 2019-06-21 |
Family
ID=67808971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016955A MX2017016955A (en) | 2017-12-20 | 2017-12-20 | Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX2017016955A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114504568A (en) * | 2022-04-21 | 2022-05-17 | 深圳市人民医院 | Application of small molecule compound in preparing medicine for inducing immunogenic cell death |
-
2017
- 2017-12-20 MX MX2017016955A patent/MX2017016955A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114504568A (en) * | 2022-04-21 | 2022-05-17 | 深圳市人民医院 | Application of small molecule compound in preparing medicine for inducing immunogenic cell death |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500284A1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
MX2018006217A (en) | Apelin receptor agonists and methods of use. | |
PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
MX2021001884A (en) | Pyrazine compounds and uses thereof. | |
PH12021550779A1 (en) | Sting agonistic compound | |
MX2021002998A (en) | Triazolo-pyrimidine compounds and uses thereof. | |
EA201691590A1 (en) | BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS | |
MX2018004344A (en) | 2,4-dihydroxy-nicotinamides as apj agonists. | |
MX2018011100A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies. | |
MX2019003363A (en) | Pharmaceutical compositions for use in the therapy of blepharitis. | |
MX2020001404A (en) | Dihydrooxadiazinones. | |
TW201613594A (en) | Pharmaceutical composition containing diamino heteroring carboxamide derivatives | |
WO2018044369A3 (en) | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer | |
JOP20210318A1 (en) | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | |
EA032654B9 (en) | [1,2,4]TRIAZOLO[4,3-b]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
MX2017016955A (en) | Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. | |
EA201700286A1 (en) | MACROMOLECULAR COMPLEXES OF TRANSITIONAL METAL FOR CANCER TREATMENT AND METHOD OF OBTAINING THEM | |
EA201792676A1 (en) | JAK1 INHIBITORS | |
EA032385B9 (en) | Pharmaceutical composition for treating gastrointestinal diseases | |
MX2019003374A (en) | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda and topoisomerase inhibitor. |